FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

OLER ABRAHAM N.
2. Issuer Name and Ticker or Trading Symbol

Onconova Therapeutics, Inc. [ ONTX ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
SVP Corp Dev & Gen Counsel
(Last)          (First)          (Middle)

12 PENNS TRAIL
3. Date of Earliest Transaction (MM/DD/YYYY)

8/2/2021
(Street)

NEWTOWN, PA 18940
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to purchase) $5.19 8/2/2021  A   40000     (1)8/2/2031 Common stock 40000 $0 40000 D  
Restricted Stock Units  (3)8/2/2021  A   13400     (2) (2)Common stock 13400 $0 13400 D  

Explanation of Responses:
(1) These options vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years.
(2) These restricted stock units vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34 % on the third anniversary.
(3) Each restricted stock unit is convertible into one share of common stock.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
OLER ABRAHAM N.
12 PENNS TRAIL
NEWTOWN, PA 18940


SVP Corp Dev & Gen Counsel

Signatures
/s/ Mark Guerin as attorney-in-fact8/4/2021
**Signature of Reporting PersonDate

Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
Von Nov 2024 bis Dez 2024 Click Here for more Onconova Therapeutics Charts.
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
Von Dez 2023 bis Dez 2024 Click Here for more Onconova Therapeutics Charts.